Aranesp – Package Leaflet: InfoCons – Consumer Protection presents, in an accessible format, the official package leaflet of the medicine Aranesp, as authorised in the European Union and published in the Union Register of medicinal products.
Before anything else
Read all of this leaflet carefully before you start using this medicine because it contains important information for you .
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects , talk to your doctor, pharmacist or nurse. This includes an y possible side effects not listed in this leaflet (see section 4).
What is i n this leaflet 1. What Aranesp is and what it is used for 2. What you need to know b efore you use Aranesp 3. How to use Aranesp 4. Possible side effects 5. How to store Aranesp 6. Contents of the pack and other information 7. Instructions for injecting with the Aranesp pre -filled syringe 1. What Aranesp is and what it is used for Your doctor has given you Aranesp (an anti -anaemic) to treat your anaemia. Anaemia is when your blood does not contain enough red blood cells and the symptoms may be fatigue, weakness and shortness of breath.
Aranesp works in exactly the same way as the natural hormone erythropoietin. Erythropoietin is produced in your kidneys and encourages your bone marrow to produce more red blood cells. The active substance of Aranesp is darbepoetin alfa produced by gene -technology in Chinese Hamster Ovary Cells (CHO -K1).
If you have chronic renal failure Aranesp is used to treat symptomatic anaemia that is associated with chronic renal failure (kidney failure) in adults and children. In kidney failure, the kidney does not produce enough of the natural hormone erythropoietin which can often cause anaemia.
Because it will take your body some time to make more red blood cells, it will be about four weeks before you notice any effect. Your normal dialysis routine will not affect the ability of Aranesp to treat your anaemia.
If you are receiving chemotherapy Aranesp is used to treat symptomatic anaemia in adult cancer patients with non -bone marrow cancers (non-myeloid malignancies) who are receiving chemotherapy.
One of the main side effects of chemotherapy is that it stops the bone marrow producing enough blood cells. Towards the end of your chemotherapy course, particularly if you have had a lot of chemotherapy, your red blood cell count may fall making you anaemic.
2. What you need to know before you use Aranesp
Do not use Aranesp
- if you are allergic to darbepoetin alfa or any of the other ingredients of this medicine listed in section 6.
- if you have been diagnosed with high blood pressure which is not being controlled with other medicines prescribed by your doctor .
Warnings and precautions
Talk to your doctor, pharmacist or nurse before using Aranesp.
Please tell your doctor if you are suffering or have suffered from :
- high blood pressure which is being controlled with medicines prescribed by your doctor;
- sickle cell anaemia;
- epileptic fits (seizures);
- convulsions (fits or seizures);
- liver disease;
- significant lack of response to medicines used to treat anaemia;
- an allergy to latex (the needle cap on the pre -filled syringe contains a derivative of latex); or
- hepatitis C.
Special warnings :
- If you have symptoms which include unusual tiredness and a lack of energy this could mean you have pure red cell aplasia (PRCA), which has been reported in patients. PRCA means that the body has stopped or reduced the production of red blood cells which causes severe anaemia.
If you experience these symptoms you should contact your doctor who will determine the best course of action to treat your anaemia.
- Take special care with other products that stimulate red blood cell production: Aranesp is one of a group of products that stimulate the production of red blood cells like the human protein erythropoietin does. Your healthcare professional should always record the exact product you are using.
- If you are a patient with chronic renal failure, and particularly if you do not respond properly to Aranesp, your doctor will check your dose of Aranesp because repeatedly increasing your dose of Aranesp if you are not responding to treatment may increase the risk of having a problem of the heart or the blood vessels and could increase risk of myocardial infarction, stroke and death.
- Your doctor should try to keep your haemoglobin between 10 and 12 g/dL. Your doctor will check that your haemoglobin does not exceed a certain level, as high haemoglobin concentrations could put you at risk of having a problem of the heart or the blood vessels and could increase risk of myocardial infarction, stroke and death.
194 – If you have symptoms which include severe headache, drowsiness, confusion, problems with your eyesight, nausea, vomiting or fits (seizures), it could mean that you have very high blood pressure. If you experience these symptoms you should con tact your doctor.
- If you are a cancer patient you should be aware that Aranesp may act as a blood cell growth factor and in some circumstances may have a negative impact on your cancer. Depending on your individual situation a blood transfusion may be preferable. Please discuss this with your doctor.
- Misuse by healthy people can cause life -threatening problems with the heart or blood vessels.
- Serious skin reactions including Stevens -Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in association with epoetin treatment. SJS/TEN can appear initially as reddish target -like spots or circular patches often with central blisters on the trunk.
Also, ulcers of mouth, throat, nose, genitals and eyes (red and swollen eyes) can occur. These serious skin rashes are often preceded by fever and/or flu -like symptoms. The rashes may progress to widespread peeling of the skin and life-threatening complications.
If you develop a serious rash or another of these skin symptoms, stop taking Aranesp and contact your doctor or seek medical attention immediately.
Other medicines and Aranesp
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
Cyclosporin and tacrolimus (medicines which suppress the immune system) may be affected by the number of red cells in your blood. It is important to tell your doctor if you are taking either of these medicines.
Using Aranesp with food and drink Food and drink do not affect Aranesp.
Pregnancy and breast -feeding If you are pregnant or breast -feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Aranesp has not been tested in pregnant women. It is important to tell your doctor if you:
- are pregnant;
- think you may be pregnant; or
- plan to get pregnant.
It is not known whether darbepoetin alfa is excreted in human milk. You must stop breast -feeding if you use Aranesp.
Driving and using machines
Aranesp should not affect your ability to drive or use machinery.
Aranesp contains sodium
This medicin e contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium -free’.
195 3. How to use Aranesp Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure .
Following blood tests, your doctor has decided you need Aranesp as your haemoglobin level is 10 g/dL or less. Your doctor will tell you how much and how often you must take Aranesp in order to maintain a haemoglobin level between 10 and 12 g/dL. This may vary depending on whether you are an adult or a child.
Injecting Aranesp yourself Your doctor may decide that it is best for you or a carer to inject Aranesp. Your doctor, nurse or pharmacist will show you how to inject yourself with the pre -filled syringe. Do not try to inject yourself if you have not been trained. Never inject Aranesp into a vein yourself.
If you have chronic renal failure For all adult and paediatric patients ≥ 1 year of age with chronic renal failure, Aranesp is given as a single injection, either under your skin (subcutaneous) or into a vein (intravenous).
In order to correct your anaemia, your initial dose of Aranesp per kilogram of your body weight will be either:
- 0.75 micrograms once every two weeks, or
- 0.45 micrograms once weekly .
For adult patients not on dialysis, 1.5 micrograms /kg once month ly may also be used as the initial dose.
For all adult and paediatric patients ≥ 1 year of age with chronic renal failure, once your an aemia is corrected you will continue to receive Aranesp given as a single injection, either once a week or once every two weeks. For all adults and paediatric patients ≥ 11 years of age not on dialysis, Aranesp could also be given as an injection once monthly.
Your doctor will take regular blood samples to measure how your anaemia is responding and may adjust your dose once every four weeks as necessary in order to maintain long term control of your anaemia .
Your doctor will use the lowest effective dose to control the symptoms of your anaemia.
If you do not respond adequately to Aranesp, your doctor will check your dose and will inform you if you need to change doses of Aranesp.
Your blood pressure will also be checked regularly, particularly at the beginning of your treatment.
In some cases, your doctor may recommend that you take iron supplements.
Your doctor may decide to change the way that your injection is given (either under the skin or into a vein). If this changes you will start on the same dose as you have been receiving and your doctor will take blood samples to make sure that your anaemia is still being managed correctly.
If your doctor has decided to change your treatment from r -HuEPO (erythropoietin produced by gene -technology) to Aranesp, they will choose whether you should receive your Aranesp injection once weekly or once every two weeks. The route of injection is the same as with r -HuEPO but your doctor will tell you how much you should take, and when, and may adjust your dose if necessary.
196 If you are receiving chemotherapy Aranesp is given as a single injection, either once a week or once every three weeks, under your skin.
In order to correct your anaemia, your initial dose will be :
- 500 micrograms once every three weeks (6.75 micrograms of Aranesp per kilogram of your body weight ); or
- 2.25 micrograms (once weekly) of Aranesp per kilogram of your body weight.
Your doctor will take regular blood samples to measure how your anaemia is responding and may adjust your dose as necessary. Your treatment will continue until approximately four weeks after the end of your chemotherapy. Your doctor will tell you exactly when to stop taking Aranesp.
In some cases, your doctor may recommend that you take iron supplements.
If you use more Aranesp than you should
You could have serious problems if you use more Aranesp than you need , such as very high blood pressure . You should contact your doctor, nurse or pharmacist if this does happen. If you feel unwell in any way you should contact your doctor, nurse or pharmacist immediately.
If you forget to use Aranesp
Do not use a double dose to make up for a forgotten dose.
If you have forgotten a dose of Aranesp, you should contact your doctor to discuss when you should inject the next dose.
If you stop using Aranesp
If you want to stop using Aranesp, you should discuss it with your doctor first .
4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects have been experienced by some patients taking Aranesp:
Chronic renal failure patients
Very common : may affect more than 1 in 10 people
- High blood pressure (hypertension)
- Allergic reactions
Common : may affect up to 1 in 10 people
- Stroke
- Pain around the area injected
- Rash and/or redness of the skin
Uncommon : may affect up to 1 in 100 people
- Blood clots (thrombosis)
- Convulsions (fits and seizures)
- Bruising and bleeding at the site of injection
- Blood clot s in a dialysis access 197 Not known : frequency cannot be estimated from available data
- Pure red cell aplasia (PRCA) – (anaemia, unusual tiredness, lack of energy) Cancer patients
Very common: may affect more than 1 in 10 people
- Allergic reactions
Common: may affect up to 1 in 10 people
- High blood pressure (hypertension)
- Blood clots (thrombosis)
- Pain around the area injected
- Rash and/or redness of the skin
- Fluid retention (oedema)
Uncommon: may affect up to 1 in 100 people
- Convulsions (fits and seizures)
- Bruising and bleeding at the site of injection All patients
Not known : frequency cannot be estimated from available data
- Serious allergic reactions which may include:
- Sudden life -threatening allergic reactions (anaphylaxis)
- Swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing (angioedema)
- Shortness of breath (allergic bronchospasm)
- Skin rash
- Hives (urticaria)
- Serious skin rashes including Stevens -Johnson syndrome and toxic epidermal necrolysis have been reported in association with epoetin treatment. These can appear as reddish target -like macules or circular patches often with central blisters on the trunk, skin peeling, ulcers of mouth, throat, nose, genitals and eyes and can be preceded by fever and flu -like symptoms.
Stop using Aranesp if you develop these symptoms and contact your doctor or seek medical attention immediately (see section 2).
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V . By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Aranesp Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on the pre -filled syringe label after EXP. The expiry date refers to the last day of that month.
Store in a refrigerator (2 °C – 8°C). Do not freeze. Do not use Aranesp if you think it has been frozen.
Keep the pre-filled syringe in the outer carton in order to protect from light.
198 When your syringe has been removed from the refrigerator and left at room temperature for approximately 30 minutes before injection it must either be used within 7 days or disposed of.
Do not use this medicine if you notice the pre -filled syringe contents are cloudy or there are particles in it.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Aranesp contains
- The active substance is darbepoetin alfa , r-HuEPO (erythropoietin produced by gene –
technology) . The pre -filled syringe contains either 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 300 or 500 micrograms of darbepoetin alfa.
- The other ingredients are sodium phosphate monobasic, sodium phosphate dibasic, sodium chloride, polysorbate 80 and water for injections.
What Aranesp looks like and contents of the pack
Aranesp is a clear, colourless or slightly pearly solution for injection in a pre -filled syringe .
Aranesp is available in packs of 1 or 4 pre -filled syringes. The syringes are provided either with (1- and 4-pack) or without (1 -pack) a blister -wrapping. Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
Amgen Europe B.V.
Minervum 7061 4817 ZK Breda The Netherlands
Marketing Authorisation Holder
Amgen Europe B.V.
Minervum 7061 4817 ZK Breda The Netherlands
Manufacturer
Amgen Technology (Ireland) Unlimited Company Pottery Road Dun Laoghaire Co Dublin Ireland
Manufacturer
Amgen NV Telecomlaan 5 -7 1831 Diegem Belgium 199 For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder :
België/Belgique/Belgien s.a. Amgen n.v.
Tel/Tél: +32 (0)2 7752711 Lietuva Amgen Switzerland AG Vilniaus filialas Tel: +370 5 219 7474 България Амджен България ЕООД Тел.: +359 (0)2 424 7440 Luxembourg/Luxemburg s.a. Amgen Belgique/Belgien Tel/Tél: +32 (0)2 7752711 Česká republika Amgen s.r.o.
Tel: +420 221 773 500 Magyarország Amgen Kft.
Tel.: +36 1 35 44 700 Danmark Amgen, filial af Amgen AB, Sverige Tlf: +45 39617500 Malta Amgen B.V.
The Netherlands Tel: +31 (0)76 5732500 Deutschland AMGEN GmbH Tel.: +49 89 1490960 Nederland Amgen B.V.
Tel: +31 (0)76 5732500 Eesti Amgen Switzerland AG Vilniaus filialas Tel: + 372 586 09553 Norge Amgen AB Tel: +47 23308000 Ελλάδα Amgen Ελλάς Φαρμακευτικά Ε.Π.Ε.
Τηλ.: +30 210 3447000 Österreich Amgen GmbH Tel: +43 (0)1 50 217 España Amgen S.A.
Tel: +34 93 600 18 60 Polska Amgen Biotechnologia Sp. z o.o.
Tel.: +48 22 581 3000 France Amgen S.A.S.
Tél: +33 (0)9 69 363 363 Portugal Amgen Biofarmacêutica, Lda.
Tel: +351 21 422 0606 Hrvatska Amgen d.o.o.
Tel: +385 (0)1 562 57 20 România Amgen România SRL Tel: +4021 527 3000 Ireland Amgen Ireland Limited Tel: +353 1 8527400 Slovenija AMGEN zdravila d.o.o.
Tel: +386 (0)1 585 1767 Ísland Vistor hf.
Sími: +354 535 7000 Slovenská republika Amgen Slovakia s.r.o.
Tel: +421 2 321 114 49 200 Italia Amgen S.r.l Tel: +39 02 6241121 Suomi/Finland Amgen AB, sivuliike Suomessa/Amgen AB, filial i Finland Puh/Tel: +358 (0)9 54900500 Kύπρος C.A. Papaellinas Ltd Τηλ.: +357 22741 741 Sverige Amgen AB Tel: +46 (0)8 6951100 Latvija Amgen Switzerland AG Rīgas filiāle Tel: + 371 257 25888 United Kingdom (Northern Ireland) Amgen Limited Tel: +44 (0)1223 420305
This leaflet was last revised in
Other sources of information Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu .
This leaflet is available in all EU/EEA languages on the European Medicines Agency website.
7. Instructions for injecting with the Aranesp pre-filled syringe This section contains information on how to give yourself an injection of Aranesp. It is important that you do not try to give yourself the injection unless you have received training from your doctor, nurse or pharmacist. If you have questions about how to inject, please ask your doctor, nurse or pharmacist for assistance.
How do you or the person injecting you, use the Aranesp pre -filled syringe?
Your doctor has prescribed an Aranesp pre -filled syringe for injection into the tissue just under the skin. Your doctor, nurse or pharmacist will tell you how much Aranesp you need and how frequently it should be injected.
Equipment:
To give yourself an injection you will need:
- a new Aranesp pre -filled syringe; and
- alcohol wipes or similar.
What should I do before I give myself a subcutaneous injection of Aranesp?
1. Remove the pre -filled syringe from the refrigerator. Leave the pre -filled syringe at room temperature for approximately 30 minutes. This will make the injection more comfortable. Do not warm Aranesp in any other way (for example, do not warm it in a microwave or in hot water). Additionally, do not leave the syringe exposed to direct sunlight.
2. Do not shake the pre -filled syringe.
3. Do not remove the cap from the syringe until you are ready to inject.
4. Check that it is the correct dose that your doctor has prescribed.
201 5. Check the expiry date on the pre -filled syringe label (EXP). Do not use it if the date has passed the last day of the month shown.
6. Check the appearance of Aranesp. It must be a clear, colourless or slightly pearly liquid. If it is cloudy or there are particles in it, you must not use it.
7. Wash your hands thoroughly.
8. Find a comfortable, well -lit, clean surface and put all the equipment you need within reach.
How do I prepare my Aranesp injection?
Before you inject Aranesp you must do the following:
1. To avoid bending the needle, gently pull the cap from the needle without twisting as shown in pictures 1 and 2.
2. Do not touch the needle or push the plunger.
3. You may notice a small air bubble in the pre -filled syringe. You do not have to remove the air bubble before injecting. Injecting the solution with the air bubble is harmless.
4. You can now use the pre -filled syringe.
Where should I give my injection?
The best places to inject yourself are the top of your thighs and the abdomen. If someone else is injecting for you, they can also use the back of your arms.
You may change the injection site if you notice the area is red or sore.
How do I give my injection?
1. Disinfect your skin by using an alcohol wipe and pinch (without squeezing) the skin between your thumb and forefinger.
2. Insert the needle fully into the skin as shown by your doctor , nurse or pharmacist .
3. Inject the prescribed dose subcutaneously as directed by your doctor, nurse or pharmacist.
4. Push the plunger with a slow constant pressure, always keeping your skin pinched, until the syringe is empty.
5. Remove the needle and let go of your skin.
6. If you notice a spot of blood you may gently dab it away with a cotton ball or tissue. Do not rub the injection site. If needed, you may cover the injection site with a plaster.
7. Only use each syringe for one injection. Do not use any Aranesp that is left in the syringe.
Remember: If you have any problems, please do not be afraid to ask your doctor or nurse for help and advice.
202 Disposing of used syringes
- Do not put the cap back on used needles, as you may accidentally prick yourself.
- Keep used syringes out of the reach and sight of children.
- The used pre -filled syringe should be disposed of in accordance with local requirements. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
203 Package leaflet: Information for the user Aranesp 10 micrograms solution for injection in pre -filled pen (SureClick) Aranesp 15 micrograms solution for injection in pre -filled pen (SureClick) Aranesp 20 micrograms solution for injection in pre -filled pen (SureClick) Aranesp 30 micrograms solution for injection in pre -filled pen (SureClick) Aranesp 40 micrograms solution for injection in pre -filled pen (SureClick) Aranesp 50 micrograms solution for injection in pre -filled pen (SureClick) Aranesp 60 micrograms solution for injection in pre -filled pen (SureClick) Aranesp 80 micrograms solution for injection in pre -filled pen (SureClick) Aranesp 100 micrograms solution for injection in pre -filled pen (SureClick) Aranesp 130 micrograms solution for injection in pre -filled pen (SureClick) Aranesp 150 micrograms solution for injection in pre -filled pen (SureClick) Aranesp 300 micrograms solution for injection in pre -filled pen (SureClick) Aranesp 500 micrograms solution for injection in pre -filled pen (SureClick) darbepoetin alfa Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse . This includes any possible side effects not listed in this leaflet (see section 4).
ℹ️ 1. What Aranesp is and what it is used for
Your doctor has given you Aranesp (an anti -anaemic) to treat your anaemia. Anaemia is when your blood does not contain enough red blood cells and the symptoms may be fatigue, weakness and shortness of breath.
Aranesp works in exactly the same way as the natural hormone erythropoietin. Erythropoietin is produced in your kidneys and encourages your bone marrow to produce more red blood cells. The active substance of Aranesp is darbepoetin alfa produced by gene -technology in Chinese Hamster Ovary Cells (CHO -K1).
If you have chronic renal failure Aranesp is used to treat symptomatic anaemia that is associated with chronic renal failure (kidney failure) in adults and children. In kidney failure, the kidney does not produce enough of the natural hormone erythropoietin which can often cause anaemia.
Because it will take your body some time to make more red blood cells, it will be about four weeks before you notice any effect. Your normal dialysis routine will not affect the ability of Aranesp to treat your anaemia.
If you are receiving chemotherapy Aranesp is used to treat symptomatic anaemia in adult cancer patients with non -bone marrow cancers (non-myeloid malignancies) who are receiving chemotherapy.
One of the main side effects of chemotherapy is that it stops the bone marrow producing enough blood cells. Towards the end of your chemotherapy course, particularly if you have had a lot of chemotherapy, your red blood cell count may fall making you anaemic.
⚠️ 2. What you need to know before you use Aranesp
Do not use Aranesp
- if you are allergic to darbepoetin alfa or any of the other ingredients of this medicine listed in section 6.
- if you have been diagnosed with high blood pressure which is not being controlled with other medicines prescribed by your doctor .
Warnings and precautions
Talk to your doctor, pharmacist or nurse before using Aranesp.
Please tell your doctor if you are suffering or have suffered from :
- high blood pressure which is being controlled with medicines prescribed by your doctor;
- sickle cell anaemia;
- epileptic fits (seizures);
- convulsions (fits or seizures);
- liver disease;
- significant lack of response to medicines used to treat anaemia; or
- hepatitis C.
Special warnings:
- If you have symptoms which include unusual tiredness and a lack of energy this could mean you have pure red cell aplasia (PRCA), which has been reported in patients. PRCA means that the body has stopped or reduced the production of red blood cells which causes severe anaemia.
If you experience these symptoms you should contact your doctor who will determine the best course of action to treat your anaemia.
- Take special care with other products that stimulate red blood cell production: Aranesp is one of a group of products that stimulate the production of red blood cells like the human protein erythropoietin does. Your healthcare professional should always record the exact product you are using.
- If you are a patient with chronic renal failure, and particularly if you do not respond properly to Aranesp, your doctor will check your dose of Aranesp because repeatedly increasing your dose of Aranesp if you are not responding to treatment may increase the risk of having a problem of the heart or the blood vessels and could increase risk of myocardial infarction, stroke and death.
- Your doctor should try to keep your haemoglobin between 10 and 12 g/dL. Your doctor will check that your haemoglobin does not exceed a certain level, as high haemoglobin concentrations could put you at risk of having a problem of the heart or the blood vessels and could increase risk of myocardial infarction, stroke and death.
- If you have symptoms which include severe headache, drowsiness, confusion, problems with your eyesight, nausea, vomiting or fits (seizures), it could mean that you have very high blood pressure. If you experience these symptoms you should con tact your doctor.
- If you are a cancer patient you should be aware that Aranesp may act as a blood cell growth factor and in some circumstances may have a negative impact on your cancer. Depending on your individual situation a blood transfusion may be preferable. Please discuss this with your doctor.
237 – Misuse by healthy people can cause life -threatening problems with the heart or blood vessels.
- Serious skin reactions including Stevens -Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in association with epoetin treatment. SJS/TEN can appear initially as reddish target -like spots or circular patches often with central blisters on the trunk.
Also, ulcers of mouth, throat, nose, genitals and eyes (red and swollen eyes) can occur. These serious skin rashes are often preceded by fever and/or flu -like symptoms. The rashes may progress to widespread peeling of the skin and life -threatening complications.
If you develop a serious rash or another of these skin symptoms, stop taking Aranesp and contact your doctor or seek medical attention immediately.
Other medicines and Aranesp
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
Cyclosporin and tacrolimus (medicines which suppress the immune system) may be affected by the number of red cells in your blood. It is important to tell your doctor if you are taking either of these medicines.
Using Aranesp with food and drink Food and drink do not affect Aranesp.
Pregnancy and breast -feeding If you are pregnant or breast -feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Aranesp has not been tested in pregnant women. It is important to tell your doctor if you:
- are pregnant;
- think you may be pregnant; or
- plan to get pregnant.
It is not known whether darbepoetin alfa is excreted in human milk. You must stop breast -feeding if you use Aranesp.
Driving and using machines
Aranesp should not affect your ability to drive or use machinery.
Aranesp contains sodium
This medicin e contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium -free’.
💊 3. How to use Aranesp
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Following blood tests, your doctor has decided you need Aranesp as your haemoglobin level is 10 g/dL or less. Your doctor will tell you how much and how often you must take Aranesp in order to maintain a haemoglobin level between 10 and 12 g/dL. This may vary depending on whether you are an adult or a child.
The injections will be given by a healthcare professional .
If you have chronic renal failure For all adult and paediatric patients ≥ 1 year of age with chronic renal failure, Aranesp is given as a single injection by a healthcare professional, either under your skin (subcutaneous) or into a vein (intravenous).
In order to correct your anaemia, your initial dose of Aranesp per kilogram of your body weight will be either:
- 0.75 micrograms once every two weeks, or
- 0.45 micrograms once weekly .
For adult patients not on dialysis, 1.5 micrograms /kg once monthly may also be used as the initial dose.
For all adult and paediatric patients ≥ 1 year of age with chronic renal failure, once your an aemia is corrected you will continue to receive Aranesp given as a single injection, either once a week or once every two week s. For all adults and paediatric patients ≥ 11 years of age not on dialysis, Aranesp could also be given as an injection once monthly.
Your doctor will take regular blood samples to measure how your anaemia is responding and may adjust your dose once every four weeks as necessary in order to maintain long term control of your anaemia.
Your doctor will use the lowest effective dose to control the symptoms of your anaemia.
If you do not respond adequately to Aranesp, your doctor will check your dose and will inform you if you need to change doses of Aranesp.
Your blood pressure will also be checked regularly, particularly at the beginning of your treatment.
In some cases, your doctor may recommend that you take iron supplements.
Your doctor may decide to change the way that your injection is given (either under the skin or into a vein). If this changes you will start on the same dose as you have been receiving and your doctor will take blood samples to make sure that your anaemia is still being managed correctly.
If your doctor has decided to change your treatment from r -HuEPO (erythropoietin produced by gene -technology) to Aranesp, they will choose whether you should receive your Aranesp injection once weekly or once every two weeks. The route of injection is the same as with r -HuEPO but your doctor will tell you how much you should take, and when, and may adjust your dose if necessary.
If you are receiving chemotherapy Aranesp is given as a single injection, either once a week or once every three weeks, under your skin.
In order to correct your anaemia, your initial dose will be :
- 500 micrograms once every three weeks (6.75 micrograms of Aranesp per kilogram of your body weight ); or
- 2.25 micrograms (once weekly) of Aranesp per kilogram of your body weight.
Your doctor will take regular blood samples to measure how your anaemia is responding and may adjust your dose as necessary. Your treatment will continue until approximately four weeks after the end of your chemotherapy. Your doctor will tell you exactly when to stop taking Aranesp.
In some cases, your doctor may recommend that you take iron supplements.
239 If you use more Aranesp than you should You could have serious problems if you receive more Aranesp than you need , such as very high blood pressure . You should contact your doctor, nurse or pharmacist if this does happen. If you feel unwell in any way you should contact your doctor, nurse or pharmacist immediately.
If you miss a dose of Aranesp Do not use a double dose to make up for a forgotten dose.
If you miss a dose of Aranesp, you should contact your doctor to discuss when you should receive the next dose.
If you stop using Aranesp
If you want to stop using Aranesp, you should discuss it with your doctor first .
❗ 4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects have been experienced by some patients taking Aranesp:
Chronic renal failure patients
Very common: may affect more than 1 in 10 people
- High blood pressure (hypertension)
- Allergic reactions
Common: may affect up to 1 in 10 people
- Stroke
- Pain around the area injected
- Rash and/or redness of the skin
Uncommon: may affect up to 1 in 100 people
- Blood clots (thrombosis)
- Convulsions (fits and seizures)
- Bruising and bleeding at the site of injection
- Blood clots in a dialysis access
Not known: frequency cannot be estimated from available data
- Pure red cell aplasia (PRCA) – (anaemia, unusual tiredness, lack of energy) Cancer patients
Very common: may affect more than 1 in 10 people
- Allergic reactions
Common: may affect up to 1 in 10 people
- High blood pressure (hypertension)
- Blood clots (thrombosis)
- Pain around the area injected
- Rash and/or redness of the skin
- Fluid retention (oedema) 240 Uncommon: may affect up to 1 in 100 people
- Convulsions (fits and seizures)
- Bruising and bleeding at the site of injection All patients
Not known: frequency cannot be estimated from available data
- Serious allergic reactions which may include:
- Sudden life -threatening allergic reactions (anaphylaxis)
- Swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing (angioedema)
- Shortness of breath (allergic bronchospasm)
- Skin rash
- Hives (urticaria)
- Serious skin rashes including Stevens -Johnson syndrome and toxic epidermal necrolysis have been reported in association with epoetin treatment. These can appear as reddish target -like macules or circular patches often with central blisters on the trunk, skin peeling, ulcers of mouth, throat, nose, genitals and eyes and can be preceded by fever and flu -like symptoms. Stop using Aranesp if you develop these symptoms and contact your doctor or seek medical attention immediately (see section 2).
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V . By reporting side effects you can help provide more information on the safety of this medicine.
🌡️ 5. How to store Aranesp
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on the vial label after EXP. The expiry date refers to the last day of that month.
Store in a refrigerator (2 °C – 8°C). Do not freeze. Do not use Aranesp if you think it has been frozen.
Keep the vial in the outer carton in order to protect from light.
When your vial has been removed from the refrigerator and left at room temperature for approximately 30 minutes before injection it must either be used within 7 days or disposed of.
Do not use this medicine if you notice the vial contents are cloudy or there are particles in it.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
📦 6. Contents of the pack and other information
What Aranesp contains
- The active substance is darbepoetin alfa, r -HuEPO (erythropoietin produced by gene –
technology). The vial contains either 25, 40, 60, 100, 200 or 300 micrograms of darbepoetin alfa.
241 – The other ingredients are sodium phosphate monobasic, sodium phosphate dibasic, sodium chloride, polysorbate 80 and water for injections.
What Aranesp looks like and contents of the pack
Aranesp is a clear, colourless or slightly pearly solution for injection in vial.
Aranesp is available in packs of 1 or 4 vials . Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
Amgen Europe B.V.
Minervum 7061 4817 ZK Breda The Netherlands
Marketing Authorisation Holder
Amgen Europe B.V.
Minervum 7061 4817 ZK Breda The Netherlands
Manufacturer
Amgen Technology (Ireland) Unlimited Company Pottery Road Dun Laoghaire Co Dublin Ireland
Manufacturer
Amgen NV Telecomlaan 5 -7 1831 Diegem Belgium For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder :
België/Belgique/Belgien s.a. Amgen n.v.
Tel/Tél: +32 (0)2 7752711 Lietuva Amgen Switzerland AG Vilniaus filialas Tel: +370 5 219 7474 България Амджен България ЕООД Тел.: +359 (0)2 424 7440 Luxembourg/Luxemburg s.a. Amgen Belgique/Belgien Tel/Tél: +32 (0)2 7752711 Česká republika Amgen s.r.o.
Tel: +420 221 773 500 Magyarország Amgen Kft.
Tel.: +36 1 35 44 700 Danmark Amgen , filial af Amgen AB, Sverige Tlf: +45 39617500 Malta Amgen B.V.
The Netherlands Tel: +31 (0)76 5732500 242 Deutschland AMGEN GmbH Tel.: +49 89 1490960 Nederland Amgen B.V.
Tel: +31 (0)76 5732500 Eesti Amgen Switzerland AG Vilniaus filialas Tel: + 372 586 09553 Norge Amgen AB Tel: +47 23308000 Ελλάδα Amgen Ελλάς Φαρμακευτικά Ε.Π.Ε.
Τηλ.: +30 210 3447000 Österreich Amgen GmbH Tel: +43 (0)1 50 217 España Amgen S.A.
Tel: +34 93 600 18 60 Polska Amgen Biotechnologia Sp. z o.o.
Tel.: +48 22 581 3000 France Amgen S.A.S.
Tél: +33 (0)9 69 363 363 Portugal Amgen Biofarmacêutica, Lda.
Tel: +351 21 422 0606 Hrvatska Amgen d.o.o.
Tel: +385 (0)1 562 57 20 România Amgen România SRL Tel: +4021 527 3000 Ireland Amgen Ireland Limited Tel: +353 1 8527400 Slovenija AMGEN zdravila d.o.o.
Tel: +386 (0)1 585 1767 Ísland Vistor hf.
Sími: +354 535 7000 Slovenská republika Amgen Slovakia s.r.o.
Tel: +421 2 321 114 49 Italia Amgen S.r.l Tel: +39 02 6241121 Suomi/Finland Amgen AB, sivuliike Suomessa/Amgen AB, filial i Finland Puh/Tel: +358 (0)9 54900500 Kύπρος C.A. Papaellinas Ltd Τηλ.: +357 22741 741 Sverige Amgen AB Tel: +46 (0)8 6951100 Latvija Amgen Switzerland AG Rīgas filiāle Tel: + 371 257 25888 United Kingdom (Northern Ireland) Amgen Limited Tel: +44 (0)1223 420305
This leaflet was last revised in
Other sources of information Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu .
This leaflet is available in all EU/EEA languages on the European Medicines Agency website.
📄 Package Leaflet – official source
This article reproduces the information in the official package leaflet, as authorised in the European Union. You can consult the original document here: Product information Aranesp (PDF, ec.europa.eu).
You can check this medicine at any time in the Union Register of medicinal products (EU number EU/1/01/185).
⚠️ Important: This article is for information purposes only and does not replace medical advice or the package leaflet inside the medicine box. Read the leaflet carefully before use. For any questions about your treatment, talk to your doctor or pharmacist. If you experience side effects, tell your doctor or pharmacist and report them through your national reporting system.